Display options
Cite
Papaioannou A, Kennedy CC, Freitag A, et al. Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial). Chest. 2008;134(4):794-800doi: 10.1378/chest.08-0608.
Papaioannou, A., Kennedy, C. C., Freitag, A., Ioannidis, G., O'Neill, J., Webber, C., Pui, M., Berthiaume, Y., Rabin, H. R., Paterson, N., Jeanneret, A., Matouk, E., Villeneuve, J., Nixon, M., & Adachi, J. D. (2008). Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial). Chest, 134(4), 794-800. https://doi.org/10.1378/chest.08-0608
Papaioannou, Alexandra, et al. "Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial)." Chest vol. 134,4 (2008): 794-800. doi: https://doi.org/10.1378/chest.08-0608
Papaioannou A, Kennedy CC, Freitag A, Ioannidis G, O'Neill J, Webber C, Pui M, Berthiaume Y, Rabin HR, Paterson N, Jeanneret A, Matouk E, Villeneuve J, Nixon M, Adachi JD. Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial). Chest. 2008 Oct;134(4):794-800. doi: 10.1378/chest.08-0608. Epub 2008 Jul 18. PMID: 18641106; PMCID: PMC5104558.
Copy Download .nbib Format: NLM
Share it on

Chest. 2008 Oct;134(4):794-800. doi: 10.1378/chest.08-0608. Epub 2008 Jul 18.

Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial).

Chest

Alexandra Papaioannou, Courtney C Kennedy, Andreas Freitag, George Ioannidis, John O'Neill, Colin Webber, Margaret Pui, Yves Berthiaume, Harvey R Rabin, Nigel Paterson, Alphonse Jeanneret, Elias Matouk, Josee Villeneuve, Madeline Nixon, Jonathan D Adachi

Affiliations

  1. Department of Medicine, McMaster University, Hamilton, ON, Canada. Electronic address: [email protected].
  2. Department of Medicine, McMaster University, Hamilton, ON, Canada.
  3. Department of Nuclear Medicine, Hamilton Health Sciences, Hamilton, ON, Canada.
  4. Department of Diagnostic Imaging, Scarborough Hospital, Scarborough, ON, Canada.
  5. Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
  6. Adult Cystic Fibrosis Clinic, University of Calgary Medical Clinic of the Foothills Medical Center, Calgary, AB, Canada.
  7. Schulich School of Medicine and Dentistry, University of Western Ontario, London Health Science Centre, London, ON, Canada.
  8. Montreal Chest Institute, Montreal, QC, Canada.
  9. Le Centre Hospitalier Universitaire de Québec, Quebec City, QC, Canada.

PMID: 18641106 PMCID: PMC5104558 DOI: 10.1378/chest.08-0608

Abstract

BACKGROUND: Patients with cystic fibrosis (CF) are at risk for early bone loss, and demonstrate increased risks for vertebral fractures and kyphosis. A multicenter, randomized, controlled trial was conducted to assess the efficacy, tolerability, and safety of therapy with oral alendronate (FOSAMAX; Merck; Whitehouse Station, NJ) in adults with CF and low bone mass.

METHODS: Participants received placebo or alendronate, 70 mg once weekly, for 12 months. All participants received 800 IU of vitamin D and 1,000 mg of calcium daily. Adults with confirmed CF with a bone mineral density (BMD) T score of < - 1.0 were eligible for inclusion. Participants who had undergone organ transplantation or had other reported contraindications were excluded from the study. The primary outcome measure was the mean (+/- SD) percentage change in lumbar spine BMD after 12 months. Secondary measures included the percentage change in total hip BMD, the number of new vertebral fractures (grade 1 or 2), and changes in quality of life.

RESULTS: A total of 56 participants were enrolled in the study (mean age, 29.1 +/- 8.78 years; 61% male). The absolute percentage changes in lumbar spine and total hip BMDs at follow-up were significantly higher in the alendronate therapy group (5.20 +/- 3.67% and 2.14 +/- 3.32%, respectively) than those in the control group (- 0.08 +/- 3.93% and - 1.3 +/- 2.70%, respectively; p < 0.001). At follow-up, two participants (both in the control group) had a new vertebral fracture (not significant), and there were no differences in quality of life or the number of adverse events (including serious and GI-related events).

CONCLUSION: Alendronate therapy was well tolerated and produced a significantly greater increase in BMD over 12 months compared with placebo.

References

  1. Transplantation. 1999 Jul 27;68(2):220-7 - PubMed
  2. N Engl J Med. 2004 Mar 18;350(12):1189-99 - PubMed
  3. Drugs. 2004;64(2):133-47 - PubMed
  4. Ann Intern Med. 2007 Mar 20;146(6):416-24 - PubMed
  5. Arch Intern Med. 2004 May 24;164(10):1108-12 - PubMed
  6. J Clin Endocrinol Metab. 2005 Mar;90(3):1888-96 - PubMed
  7. J Clin Densitom. 2000 Fall;3(3):281-90 - PubMed
  8. BMC Musculoskelet Disord. 2005 Jul 11;6:39 - PubMed
  9. N Engl J Med. 2006 Aug 17;355(7):675-84 - PubMed
  10. Chest. 1998 Jan;113(1):217-26 - PubMed
  11. Thorax. 2004 Jul;59(7):613-7 - PubMed
  12. Thorax. 2004 Aug;59(8):699-703 - PubMed
  13. CMAJ. 2000 Aug 8;163(3):265-71 - PubMed
  14. Ir Med J. 2005 Oct;98(9):270-3 - PubMed
  15. Am J Respir Crit Care Med. 2004 Jan 1;169(1):77-82 - PubMed
  16. Arch Pediatr. 2004 Dec;11(12):1445-9 - PubMed
  17. Lancet. 1998 Nov 28;352(9142):1753-4 - PubMed
  18. J Bone Miner Res. 2005 Jan;20(1):141-51 - PubMed
  19. Clin Rheumatol. 2007 Feb;26(2):161-7 - PubMed
  20. J Bone Miner Res. 1995 Jun;10(6):997-8 - PubMed
  21. Clin Chest Med. 2007 Jun;28(2):279-88 - PubMed
  22. Curr Med Res Opin. 2007 Jun;23(6):1341-9 - PubMed
  23. Ann N Y Acad Sci. 2006 Dec;1092:397-402 - PubMed
  24. J Heart Lung Transplant. 2006 Jul;25(7):745-55 - PubMed
  25. Osteoporos Int. 2006;17(5):716-23 - PubMed
  26. Am J Respir Crit Care Med. 2006 Aug 1;174(3):306-11 - PubMed
  27. J Orthop Surg Res. 2007 May 21;2:9 - PubMed
  28. Thorax. 2001 Apr;56(4):314-6 - PubMed
  29. Curr Opin Pulm Med. 2006 Nov;12(6):453-8 - PubMed
  30. Osteoporos Int. 2003 Nov;14(11):913-7 - PubMed

Substances

MeSH terms

Publication Types

Grant support